Drugs & Targets FDA approves Oncomine Dx Target Test as CDx for Rybrevant December 10, 2021Vol.47 No.45
Drugs & Targets FDA accepts sBLA for BMS’ Reblozyl for priority review in adults with non-transfusion dependent beta thalassemia December 10, 2021Vol.47 No.45
Regulatory News FDA cancels second ODAC in a row as two accelerated approval drugs are yanked by sponsors (and one still dangles) December 03, 2021Vol.47 No.44By Alice Tracey
In Brief Robert Califf receives support from 54 organizations to be commissioner of the FDA December 03, 2021Vol.47 No.44
Drugs & Targets FDA approves Fyarro for malignant perivascular epithelioid cell tumor December 03, 2021Vol.47 No.44
Drugs & Targets FDA approves Darzalex Faspro, Kyprolis, and Dexamethasone for multiple myeloma December 03, 2021Vol.47 No.44
Drugs & Targets FDA approves Cytalux for identifying malignant ovarian cancer lesions December 03, 2021Vol.47 No.44
Drugs & Targets FDA grants orphan drug designation to UV1 cancer vaccine in metastatic melanoma December 03, 2021Vol.47 No.44
Guest EditorialHealth Equity To make clinical trials equitable, cancer groups evaluate restrictive eligibility criteria November 19, 2021Vol.47 No.43By Julia Beaver, Thomas S. Uldrick, Gwynn Ison, Suanna S. Bruinooge, Caroline Schenkel and Edward S. Kim
Drugs & Targets FDA approves Keytruda as adjuvant therapy for patients with RCC following nephrectomy November 19, 2021Vol.47 No.43
